All News
ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collected from plasma as a means of non-invasive liquid biopsy in vasculitis @RheumNow #EULAR2021 Abstr#OP0056 https://t.co/Y6UO2mpjV0
Richard Conway RichardPAConway ( View Tweet)
After this morning's great discussion at the #epidemiology interest group, Prof Nagy gives a summary of the @eular_org Definition of difficult-to-treat #RheumatoidArthritis at #EULAR2021, including a great summary of the elements and evidence behind the recommendation. https://t.co/imXECTlUbf
EMEUNET EMEUNET ( View Tweet)
Additional results from @rheum_covid trainee survey re: Telemedicine presented in AB0674:
📱dramatic ⬆️ in telemed (13% to 83%) during pandemic
📱limited training and supervision
📱trainees felt telemed negatively impacted supervision & clin teaching quality
#EULAR2021 https://t.co/44X5UprD7V
Kristen Young kristenyoung ( View Tweet)
Bariatric surgery decreases the risk of moderate-to-severe hip or knee osteoarthritis.
Burkard. OP0106
#EULAR2021 > FB https://t.co/qh1RQfcvM2
ARD & RMD Open ARD_BMJ ( View Tweet)
Presented results from @rheum_covid Trainee Survey today at #EULAR21 (POS0051):
👎🏼 trainees felt multiple domains in clinical care & research were negatively impacted by pandemic
🔥 50% felt burntout with 68% with ⬆️ of work related stress
🗣@SuAnnYeoh1, @rheumed & team https://t.co/KXei6r6ZHn
Kristen Young kristenyoung ( View Tweet)
Following this morning's excellent group discussion on #D2T #RA, Prof Nagy presents @eular_org Definition of #difficulttotreat RA at #EULAR2021
D2T disease, consider:
👉🏼Treatment history
👉🏼Presence of one of the below factors
👉🏼Mx of difficult signs/symptoms as per clinician https://t.co/xbtKuvjLw4
Mrinalini Dey DrMiniDey ( View Tweet)
Moysidou et al reviewed pubmed registries/longitudinal cohort studies in PsA. 27 registries, totaling 30 countries (67% European, 26% N. American) Africa not represented. This is a call to arms for global PsA pts! #EULAR2021 @RheumNow Poster #POS1078 https://t.co/rsQYR6NFNT https://t.co/MU3FVXuRxS
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lam presenting data on early RA and matched controls. T2T strategy led to no increased CV event risk over 5 years. Longer remission duration protective, higher baseline HAQ associated with higher risk @RheumNow #EULAR2021 Abstr#OP0103 https://t.co/MZdEoyWI64
Richard Conway RichardPAConway ( View Tweet)
We are truly blessed to live in an era when response to RA treatment is the norm.
(our forefathers looking on jealously from their gold and pencillinamine towers!)
real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv
David Liew drdavidliew ( View Tweet)
tofa/bari in RA H2H vs TNFi comparative efficacy studies highlighted (more head-to-head studies please!) @karolinskainst OP0122 #EULAR2021 @RheumNow (also Swedish national registry data showed tofa/bari comparable to non-TNFi bDMARDs, but no photos allowed!) https://t.co/CUWlK2O94h
David Liew drdavidliew ( View Tweet)
VTE/VZV in baricitinib & tofacitinib seem unrelated to on-target effects.
Is there VTE/VZV-related off-target culpable binding?
Computer (AI) says no, but...
bari binds PDE10A2 (an antipsychotic target), lab confirmed. Missing link to reduced pain?
POS0091 #EULAR2021 @RheumNow https://t.co/uqYixHhW1z
David Liew drdavidliew ( View Tweet)
Our SLR on pathogenesis of SARS-CoV-2 Main findings: TH1 cytokines and IL-6 associated w/ severe COVID19 and fatal outcomes. ⬆️ classical blood monocytes and polyfunctional T cells. Impaired IFN response associated w/ poor outcomes. #POS0052 @Rheumnow #EULAR2021 @alessia_alunno https://t.co/PGph5IRBkX
Aurelie Najm AurelieRheumo ( View Tweet)
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events.
Why all the variation?
(Until we sort that out, we'll struggle to assess JAKi post-marketing safety...)
@k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
David Liew drdavidliew ( View Tweet)
German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA pts, but the effect is evident starting between 2 and 4 years post tx induction. #EULAR2021 Abstracts #OP0137 & #OP0139 @RheumNow https://t.co/uR9rug6zqI https://t.co/xF3wcxm4cf https://t.co/lEsUvOSJ6K
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
@jeffsparks wahooo! Congrats on the #EULAR2021 clinical science award recognition!
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 #EULAR21 #eular #spondyloarthritis
I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance
Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage
@deodhara @NigilHaroon https://t.co/zwKI1o9WcO
EnvisionRheumat ERheumat ( View Tweet)
Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)